Placebo to Mexiletine granules for prolonged-release oral suspension 167 mg, 333 mg, and 500 mg, Mexiletine granules for prolonged-release oral suspension 333 mg, Mexiletine granules for prolonged-release oral suspension 500 mg, Mexiletine granules for prolonged-release oral suspension 167 mg
MEX-DM-302
Phase 3 small_molecule active
Quick answer
Placebo to Mexiletine granules for prolonged-release oral suspension 167 mg, 333 mg, and 500 mg, Mexiletine granules for prolonged-release oral suspension 333 mg, Mexiletine granules for prolonged-release oral suspension 500 mg, Mexiletine granules for prolonged-release oral suspension 167 mg for Myotonic Dystrophy type 1 and type 2 (DM1/DM2) is a Phase 3 program (small_molecule) at Lupin Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lupin Europe GmbH
- Indication
- Myotonic Dystrophy type 1 and type 2 (DM1/DM2)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active